

HUMANIZED IMMUNOGLOBULIN REACTIVE WITH B7-2 AND
METHODS OF TREATMENT THEREWITH

ABSTRACT OF THE DISCLOSURE

The invention relates to a humanized anti-B7-2 antibody that comprises a variable
5 region of nonhuman origin and at least a portion of an immunoglobulin of human
origin. The invention also pertains to methods of treatment for various autoimmune
diseases, transplant rejection, inflammatory disorders and infectious diseases by
administering humanized anti-B7-2 and/or anti-B7-1 antibodies.